A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130315212108im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
To evaluate the safety of administering Therion Recombinant Vaccinia-HIV-1 IIIB env/gag/pol Vaccine (TBC-3B) vaccinations to vaccinia-naive individuals. To evaluate the immunogenicity of priming with TBC-3B by the scarification, intradermal, and subcutaneous routes, followed by booster immunization of MN rgp120 HIV-1. To compare the immunogenicity of priming with TBC-3B in vaccinia-naive individuals to vaccinia-immune individuals.
In prior trials evaluating alternative methods of vaccine administration, scarification has been found to be an imprecise method of administration and allows only 1.0 - 2.5 microliters of immunogen to be given. Since it is not feasible to produce vaccine at concentrations higher than 10 to the 10th pfu/ml, this method limits the maximum deliverable dose. Intradermal and subcutaneous injection routes allow larger volumes of vaccinia to be given, i.e.: up to 200 microliters intradermally and up to 100 ml subcutaneously. In the present study, the initial priming dose will be the same administered by all 3 methods; however, the second priming dose administered at 2 months intradermally and subcutaneously will be 2 logs higher in order to achieve boosting of immune responses, particularly to gag and pol components of TBC-3B.
Condition | Intervention |
---|---|
HIV Infections |
Biological: MN rgp120/HIV-1 Biological: TBC-3B Vaccine |
Study Type: | Interventional |
Study Design: | Endpoint Classification: Safety Study Masking: Double-Blind Primary Purpose: Prevention |
Official Title: | A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum. |
Estimated Enrollment: | 36 |
Study Completion Date: | July 1999 |
In prior trials evaluating alternative methods of vaccine administration, scarification has been found to be an imprecise method of administration and allows only 1.0 - 2.5 microliters of immunogen to be given. Since it is not feasible to produce vaccine at concentrations higher than 10 to the 10th pfu/ml, this method limits the maximum deliverable dose. Intradermal and subcutaneous injection routes allow larger volumes of vaccinia to be given, i.e.: up to 200 microliters intradermally and up to 100 ml subcutaneously. In the present study, the initial priming dose will be the same administered by all 3 methods; however, the second priming dose administered at 2 months intradermally and subcutaneously will be 2 logs higher in order to achieve boosting of immune responses, particularly to gag and pol components of TBC-3B.
After volunteers are recruited, screened and enrolled in the study, they will be randomized to group C, D, or E. Each group will enroll 10 patients and 2 controls. The placebo control for TBC-3B will be standard vaccinia vaccination administered at doses no higher than that administered by scarification; the placebo control for MN rgp120 will be alum. Group C will receive undiluted TBC-3B by scarification, at months 0 and 2. Group D will receive diluted TBC-3B intradermally at month 0 and undiluted TBC-3B at month 2. Group E will receive diluted TBC-3B subcutaneously at month 0 and undiluted TBC-3B at month 2. At months 8 and 12 all groups will receive MN rgp 120/HIV-1 in alum intramuscularly.
![](https://webarchive.library.unt.edu/web/20130315212108im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria
Patients must have:
- Negative FDA-approved ELISA for HIV within 8 weeks of immunization.
- Normal history and physical examination.
- Negativity for Hepatitis B surface antigen.
- Availability for follow-up for planned duration of the study (18 months).
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Medical or psychiatric condition or occupational responsibilities that preclude subject compliance with the protocol. Specifically excluded are people with a history of suicide attempts, recent suicidal ideation or who have past or present psychosis.
- Active syphilis. NOTE: If the serology is documented to be a false positive or due to a remote (> 6 months) treated infection, the volunteer is eligible.
- Active tuberculosis. NOTE: Patients with a positive PPD and a normal chest X-ray showing no evidence of TB and not requiring INH therapy are eligible.
- Household contacts with, or occupational exposure to, people with any of the following:
Pregnancy. <12 months of age. Eczema or Immunodeficiency disease. Use of immunosuppressive medications.
Patients with the following prior conditions are excluded:
- History of immunodeficiency, chronic illness, malignancy or autoimmune disease.
- History of cancer, unless there has been surgical excision followed by a sufficient observation period to give a reasonable assurance of cure.
- Any history of anaphylaxis or history of other serious adverse reactions to vaccines.
- History of serious allergic reaction to any substance, requiring hospitalization or emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasm, or hypotension).
- Eczema within the past year.
- History of smallpox vaccination.
- Envelope bands on HIV-1 Western blot within 8 weeks of immunization.
Prior Medication: Excluded:
- Use of immunosuppressive.
- Live attenuated vaccines within 60 days of study.
- NOTE: Medically indicated subunit or killed vaccines (e.g. influenza, pneumococcal) do not exclude, but should be given at least 2 weeks prior to HIV immunizations.
- Experimental agents within 30 days prior to study.
- Prior receipt of HIV-1 vaccines or placebo recipient in a previous HIV vaccine trial.
Receipt of blood products or immunoglobulin within past 6 months.
Risk Behavior: Excluded:
- History of injection drug use within the last 12 months prior to enrollment.
- Higher or intermediate risk sexual behavior as defined by the AVEG.
- Lower risk sexual behavior as defined by AIDS Vaccine Evaluation Group (AVEG) procedures.
![](https://webarchive.library.unt.edu/web/20130315212108im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
United States, Maryland | |
JHU AVEG | |
Baltimore, Maryland, United States | |
United States, Missouri | |
St. Louis Univ. School of Medicine AVEG | |
Saint Louis, Missouri, United States | |
United States, Tennessee | |
Vanderbilt Univ. Hosp. AVEG | |
Nashville, Tennessee, United States, 37232 | |
United States, Washington | |
UW - Seattle AVEG | |
Seattle, Washington, United States, 98144 |
Study Chair: | Smith C |
![](https://webarchive.library.unt.edu/web/20130315212108im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Publications:
Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00000866 History of Changes |
Other Study ID Numbers: | AVEG 014C, 10562 |
Study First Received: | November 2, 1999 |
Last Updated: | May 16, 2012 |
Health Authority: | United States: Federal Government |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Vaccines, Synthetic Vaccinia Virus Placebos HIV-1 AIDS Vaccines |
HIV Seronegativity Genes, env Genes, pol Genes, gag HIV Preventive Vaccine |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Vaccinia Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Poxviridae Infections DNA Virus Infections |
ClinicalTrials.gov processed this record on March 14, 2013